BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, February 12, 2026
Home » Authors » Amanda Lanier

Articles by Amanda Lanier

IPO, coins, upward arrow
Med-tech IPO performance 2025

IPO window reopens, med-tech class of 2025 gains 26%

Feb. 12, 2026
By Amanda Lanier
No Comments
After a prolonged downturn, the med-tech IPO market rebounded in 2025, with deal value surging to $13.01 billion across 31 offerings. The recovery followed two muted years, with just $619 million raised in 2024 and a low-point of $110 million in 2023.
Read More
Hand holding dollar sign
Biopharma financings January 2026

2026 kicks off with $10.8B January financing haul

Feb. 10, 2026
By Amanda Lanier
No Comments
Total biopharma financings rose to $10.79 billion in January 2026, up from $9.08 billion in December. The monthly total nearly matched the January 2024 record of $10.9 billion, far exceeding the $6.82 billion average monthly haul in 2025.
Read More
Med-tech financings January 2026

Med-tech financing off to slow start with $1.52B raised in January

Feb. 9, 2026
By Amanda Lanier
No Comments
While in 2025 med-tech financings averaged $3.3 billion per month, January 2026 saw the sector bring in $1.52 billion across 39 transactions. It was the lowest monthly total since November 2024’s $924.59 million. However, a number of months last year saw fluctuating values, ranging from $1.65 billion in July to $8.26 billion in December 2025, indicating uncertainty as to how industry financings will shake out this year.
Read More
Hand holding dollar sign
Biopharma financings January 2026

2026 kicks off with $10.8B January financing haul

Feb. 6, 2026
By Amanda Lanier
No Comments
Total biopharma financings rose to $10.79 billion in January 2026, up from $9.08 billion in December. The monthly total nearly matched the January 2024 record of $10.9 billion, far exceeding the $6.82 billion average monthly haul in 2025.
Read More
Line graph arrow trending upward
Index insights

Cancer index surges 72% as Terns, Olema lead gains

Feb. 5, 2026
By Amanda Lanier
No Comments
The BioWorld Cancer Index closed 2025 up 72.35%, outpacing gains in the Nasdaq Biotechnology Index (up 32.4%) and the Dow Jones Industrial Average (up 12.97%). The year featured standout gains, led by Terns Pharmaceuticals Inc., which surged 620%.
Read More
Syringe and capsules atop lab chart
Biopharma clinical updates December 2025

Phase III wins propel Capricor, Belite and DBV higher in December

Feb. 2, 2026
By Amanda Lanier
No Comments
BioWorld tracked 215 clinical trial readouts spanning phases I through III in December 2025, a sizeable increase from 170 updates in November, but below the 252 reported in October.
Read More
Financial line graph
Index insights

Arrowhead gains, Agios drops as drug developers end 2025 up 34%

Jan. 30, 2026
By Amanda Lanier
No Comments
After reaching their peaks in late November, both the BioWorld Drug Developers Index and the Nasdaq Biotechnology Index finished the year slightly down from those highs.
Read More
Invest compass
Med-tech financings Q4 2025

Q4 financing boom lifts med-tech to strong 2025 finish

Jan. 30, 2026
By Amanda Lanier
Total med-tech financing activity surged in the fourth quarter of 2025, with $16.21 billion raised across all financing categories, more than double the $5.78 billion recorded in Q3 and the strongest quarterly total of the year.
Read More
Green, blue, gray dollar signs
Biopharma deals Q4 2025

Biopharma deal value peaks in 2025 after strong Q4

Jan. 27, 2026
By Amanda Lanier
No Comments
Full-year biopharma deal value in 2025 reached $292.55 billion, the highest annual total in BioWorld’s records, following $78.93 billion in the fourth quarter (Q4). The annual total is a 27% increase from the $230.53 billion recorded in 2024.
Read More
FDA approved icons and medical professional
Biopharma regulatory actions and approvals December 2025

US FDA caps 2025 with December high of 27 drug approvals

Jan. 26, 2026
By Amanda Lanier
No Comments
The U.S. FDA approved 27 drugs in December, the highest month of 2025. This compares to 18 approvals in November and brings the full year total to 226. This places 2025 just below the 228 approvals recorded in 2024 but well above approval numbers seen in most prior years of the past decade.
Read More
Previous 1 2 3 4 5 6 7 8 9 … 43 44 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Feb. 12, 2025.
  • Illustration of SCAN in Parkinson’s vs healthy subcortex

    SCAN is core circuit affected in Parkinson’s disease

    BioWorld Science
    Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
  • Woman and 3D brain

    Astellas’ ASP-2246 shows promise in stroke management

    BioWorld Science
    Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for Feb. 10, 2026
  • 3D illustration of skin layers

    TL1A is overexpressed in hidradenitis suppurativa

    BioWorld Science
    Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing